This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.90% per year. These returns cover a period from January 1, 1988 through December 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Regeneron's (REGN) Lymphoma Candidate Rejected by the FDA
by Zacks Equity Research
Regeneron's (REGN) efforts to expand its oncology portfolio get a hit as the FDA refuses to approve the lymphoma drug odronextamab.
REGNNegative Net Change ANIPPositive Net Change ADMANegative Net Change GLPGNo Net Change
biotechnology biotechs medical pharmaceuticals
AbbVie (ABBV) to Buy Landos to Strengthen Autoimmune Portfolio
by Zacks Equity Research
AbbVie (ABBV) offers to buy Landos Biopharma (LABP) to boost its portfolio in inflammatory and autoimmune disease drugs.
MRKNegative Net Change ABBVNegative Net Change CEREPositive Net Change
biotechs pharmaceuticals
Bayer (BAYRY) Banks on Pipeline Progress Amid Challenges
by Zacks Equity Research
Bayer (BAYRY) relies on pipeline candidate elinzanetant and key drugs, Nubeqa and Kerendia, to drive growth amid pipeline and regulatory setbacks.
PFENegative Net Change BAYRYPositive Net Change BBIONegative Net Change
biotechnology biotechs pharmaceuticals
Vertex (VRTX) Continues to Diversify Beyond CF Franchise
by Zacks Equity Research
While CF remains the main area of focus for Vertex Pharmaceuticals (VRTX), it is seeing success in the development of its non-CF pipeline candidates.
VRTXNegative Net Change MRNANegative Net Change CRSPPositive Net Change
biotechs
Lisata's (LSTA) LSTA1 Gets FDA's RPDD Tag for Osteosarcoma
by Zacks Equity Research
Lisata's (LSTA) lead investigational product candidate, LSTA1, gets Rare Pediatric Disease Designation for treating osteosarcoma. Stock rises.
VNDAPositive Net Change ANIPPositive Net Change ADMANegative Net Change LSTAPositive Net Change
biotechs
Vertex (VRTX) Kidney Disease Drug to Enter Clinical Development
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) plans to begin a phase I study on VX-407 in autosomal dominant polycystic kidney disease later this month.
VRTXNegative Net Change ADMANegative Net Change CRSPPositive Net Change MORPositive Net Change
biotechs
Novo Nordisk (NVO) Gets Positive CHMP Opinion for Insulin Icodec
by Zacks Equity Research
Novo Nordisk (NVO) receives a positive opinion from the CHMP for once-weekly basal insulin icodec for the treatment of diabetes in adults.
NVOPositive Net Change ANIPPositive Net Change ADMANegative Net Change GLPGNo Net Change
biotechnology biotechs pharmaceuticals
Why Argenx's (ARGX) Stock Price Moved Up 11% on Thursday
by Zacks Equity Research
Argenx (ARGX) surges after a Japanese rival posted disappointing results from a late-stage study on its investigational drug for generalized myasthenia gravis.
RHHBYNegative Net Change ADMANegative Net Change ARGXPositive Net Change IMVTNegative Net Change
biotechs medical pharmaceuticals
Merck's (MRK) Keytruda-Lynparza Combo Fails 2nd Lung Cancer Study
by Zacks Equity Research
Merck's attempt to use the Keytruda-Lynparza combination in certain non-small cell lung cancer patients has come up short with a second pivotal study failure.
AZNNegative Net Change MRKNegative Net Change ANIPPositive Net Change ADMANegative Net Change
biotechs medical pharmaceuticals vaccines
Lifecore (LFCR) Down 30% on Ending Strategic Review With No Deal
by Zacks Equity Research
Lifecore (LFCR) ends a year-long strategic review and will continue its operations on a stand-alone basis. The company also names a new CEO effective from May 20.
ANIPPositive Net Change ADMANegative Net Change GLPGNo Net Change LFCRPositive Net Change
biotechs medical
GSK Follows Rivals, to Cap Out-of-Pocket Inhaler Cost in US
by Zacks Equity Research
GSK plc (GSK) plans to lower the prices of its entire inhaled respiratory products to $35 per month in the United States. The company intends to start this in 2025.
AZNNegative Net Change GSKNo Net Change TEVAPositive Net Change ADMANegative Net Change
biotechs medical pharmaceuticals vaccines
ACELYRIN (SLRN) Up on Data From Thyroid Eye Disease Study
by Zacks Equity Research
ACELYRIN (SLRN) posts positive proof-of-concept data from a phase I/II study evaluating its pipeline candidate, lonigutamab, for treating thyroid eye disease. Stock gains.
AMGNNegative Net Change ANIPPositive Net Change ADMANegative Net Change
biotechs
Spruce Biosciences (SPRB) Falls 86% in a Month: Here's Why
by Zacks Equity Research
Spruce Biosciences' (SPRB) CAHmelia-203 phase IIb study of tildacerfont in adult patients with CAH fails to meet the primary efficacy endpoint.
VNDAPositive Net Change ADMANegative Net Change MORPositive Net Change SPRBNegative Net Change
biotechs
Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More
by Zacks Equity Research
Geron Corporation (GERN) and Crinetics Pharmaceuticals (CRNX) gain on positive regulatory and study updates.
BMYNegative Net Change GERNPositive Net Change PTCTPositive Net Change AXSMPositive Net Change CRNXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Cardiff (CRDF) Stock Rallies 194% in a Month: Here's Why
by Zacks Equity Research
Cardiff (CRDF) surges 194% in the past month, driven by investors' optimism regarding the potential of its investigational candidate, onvansertib, to treat first-line patients with RAS-mutated mCRC.
PFENegative Net Change ADMANegative Net Change CRDFNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Bristol Myers (BMY) Gets EC Nod for Abecma's Label Expansion
by Zacks Equity Research
Bristol Myers (BMY) wins European Commission's approval for the label expansion of its CAR T cell immunotherapy Abecma in earlier lines for triple-class exposed relapsed and refractory multiple myeloma.
BMYNegative Net Change ANIPPositive Net Change ADMANegative Net Change
biotechnology biotechs pharmaceuticals
PTC Therapeutics (PTCT) Up on Positive Regulatory Updates
by Zacks Equity Research
PTC Therapeutics (PTCT) submits BLA for gene therapy Upstaza to the FDA and announces plans to resubmit its application for Translarna to the regulatory body. Its shares rise on these updates.
RHHBYNegative Net Change PTCTPositive Net Change ANIPPositive Net Change ADMANegative Net Change
biotechnology biotechs medical pharmaceuticals
Axsome (AXSM) Begins Dosing in Depression Study on Sunosi
by Zacks Equity Research
Axsome (AXSM) doses the first patient in the phase III PARADIGM study evaluating Sunosi (solriamfetol) for treating major depressive disorder. The stock rises 6%.
JAZZPositive Net Change ANIPPositive Net Change ADMANegative Net Change AXSMPositive Net Change
biotechs
Crinetics (CRNX) Up as Second Acromegaly Study Meets Goals
by Zacks Equity Research
Crinetics (CRNX) stock rises after achieving goals in the second late-stage study evaluating paltusotine in patients with acromegaly who are treatment-naive or not currently receiving medical therapy.
ACETNegative Net Change ADMANegative Net Change CRNXPositive Net Change
biotechnology biotechs medical pharmaceuticals
GSK Outperforms Industry on Strength in Key Drugs & Vaccines
by Zacks Equity Research
Strong sales growth of GSK's specialty drugs and vaccines, the contribution from new products and positive pipeline updates should drive the stock in the future quarters.
GSKNo Net Change PFENegative Net Change ADMANegative Net Change HLNNegative Net Change
biotechs
Hoth Therapeutics (HOTH) Up on Upbeat Alzheimer's Drug Data
by Zacks Equity Research
Hoth Therapeutics (HOTH) rises on encouraging pre-clinical data demonstrating cognitive benefits of its novel therapeutic candidate, HT-ALZ, in the treatment of Alzheimer's disease.
ACETNegative Net Change ADMANegative Net Change HOTHNegative Net Change
biotechnology biotechs medical pharmaceuticals
Time to be "Overweight" Viking Therapeutics
by Andrew Rocco
A rising obesity rate and the desire for a quick fix are driving the burgeoning weight loss industry. Stock Strategist Andrew Rocco explains why VKTX stands to benefit the most.
GSPositive Net Change AAPLPositive Net Change NVOPositive Net Change LLYPositive Net Change GOOGLPositive Net Change VKTXNegative Net Change
biotechnology biotechs
AstraZeneca (AZN) Follows Boehringer, to Cap Inhaler Cost in US
by Zacks Equity Research
AstraZeneca (AZN) plans to lower the prices of its inhaled respiratory products to $35 per month in the United States. However, the company intends to start this in June 2024.
AZNNegative Net Change GSKNo Net Change TEVAPositive Net Change ADMANegative Net Change
biotechs medical pharmaceuticals vaccines
Intellia (NTLA) Begins Dosing in Phase III ATTR Amyloidosis Study
by Zacks Equity Research
Intellia (NTLA) doses the first patient in the phase III MAGNITUDE study on NTLA-2001 for treating transthyretin amyloidosis with cardiomyopathy.
REGNNegative Net Change ANIPPositive Net Change ADMANegative Net Change NTLAPositive Net Change
biotechs
Fennec (FENC) Signs Licensing Deal With Norgine, Stock Up
by Zacks Equity Research
Fennec (FENC) signs a licensing deal with Nordine, granting the latter rights to Pedmarqsi in the EU, Australia and New Zealand to treat cisplatin-induced hearing loss. The stock rises 11.4%.
ACETNegative Net Change ADMANegative Net Change FENCNegative Net Change
biotechnology biotechs medical pharmaceuticals